Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 31;10(1):1873530. doi: 10.1080/2162402X.2021.1873530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — NK cell numbers are reduced in SS compared to healthy and show a tendency of recovery after ECP treatment

(a) Representative FACS plot (left) and histogram (right) illustrating the gating strategy on CD3 (y-axis) and CD56 (x-axis) for CD3⁻/CD56^+dim and CD3⁻/CD56^+bright NK cells. (b) Dot plot showing the number of NK cells per µl whole blood for healthy individuals (Healthy, n = 12) and Sézary patients (SS, n = 12). (c-e) Dot plots depicting the percentage of NK cells in Sézary patients before and after ECP (both groups n = 9), ns = not significant. c) for total CD56⁺ NK cells (d) for CD56^+dim NK cells (e) for CD56^+bright NK cells. (f) Bar plots depicting the relative changes in NK cells for individual Sézary patients before and after ECP treatment, total CD56⁺ NK cells (gray), CD56^+dim NK cells (green), CD56^+bright NK cells (blue). Patients with clinical response to treatment are shown as filled bars, those without as empty bars.